Manidipine: A review of its use in hypertension

Drugs

Volumn 61, Issue 12, 2001, Pages 1777-1799

  Cheer, S M ^a   McClellan, K ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ATRIAL NATRIURETIC FACTOR; CALCIUM ANTAGONIST; CHOLESTEROL; CYTOCHROME P450; DELAPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN 1; FELODIPINE; GLUCOSE; INSULIN; LACIDIPINE; LIPOPROTEIN; MANIDIPINE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PLACEBO; PLASMA PROTEIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ANKLE EDEMA; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTECTION; QUALITY OF LIFE; RASH;

EID: 0034770462     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161120-00010     Document Type: Article

References (92)

1. Dual mode of action of dihydropyridine calcium antagonists: A role for nitric oxide
2. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
4. How to use calcium antagonists in hypertension: Putting the JNC-V1 guidelines into practice
5. The classification of calcium antagonists and their selection in the treatment of hypertension: A reappraisal
6. Calcium channel blocking action of franidipine hydrochloride (CV-4093.2HCl) in vitro and in vivo
7. Selective and long-lasting inhibitory actions of the dihydropyridine derivative, CV-4093, on calcium currents in smooth muscle cells of the rabbit pulmonary artery
8. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093. In vitro comparison with other calcium antagonists
9. Effects of manidipine hydrochloride (CV-4093.2HCl) on systemic hemodynamics, cardiac function and plasma renin activity in conscious renal hypertensive dogs
10. Effects of manidipine hydrochloride (CV-4093 (2HCI)) on hemodynamics and cardiac function in conscious normotensive dogs
11. Manidipina versus amlodipina in type II diabetic patients with hypertension: Comparison in double blind
12. Anti-hypertensive effect of manidipine: 24 hours monitoring evaluation and Doppler-echocardiographic remarks
13. Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: A double-blind, randomized, parallel group, placebo-controlled study
14. Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives
15. Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-moderate hypertension. Manidipine Efficacy in Long-Term Treatment Group
16. Efficacy of manidipine on circadian blood pressure in essential hypertension
17. Mild arterial hypertension and impaired glucose tolerance: Short-term effects of manidipine hydrochloride
18. Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus
19. Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients
20. Efficacy of manidipine in the treatment of hypertension with renal impairment: A multicenter trial
21. Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders
22. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension
23. Effects of manidipine hydrochloride on blood pressure in hypertensive patients - A comparison with nifedipine retard
24. Reduction of left ventricular mass by manidipine hydrochloride
25. Studies on the glomerular microcirculatory actions of manidipine and its modulation of the systemic and renal effects of endothelin
26. Effect of calcium antagonist, manidipine hydrochloride, on renal hemodynamics and tubuloglomerular feedback in spontaneously hypertensive rats
27. Renal effects of manidipine hydrochloride: A new calcium antagonist in hypertensive patients
28. Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension
29. Natriuretic action of manidipine hydrochloride, a new calcium channel blocker, in spontaneously hypertensive rats
30. Effects of CV-4093, a new dihydropyridine calcium channel blocker, on renal hemodynamics and function in stroke-prone spontaneously hypertensive rats (SHRSP)
31. Effects of manidipine on renal sodium and calcium handling in patients with mild essential hypertension
32. Manidipine attenuates a progressive renal injury in remnant kidneys of rats
33. Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys
34. Long-term effect of manidipine on renal function and structure in uninephrectomized spontaneously hypertensive rats
35. An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat
36. Renoprotection of calcium antagonist: Effect of manidipine on urinary microalbumin excretion and lipid peroxidation
37. Effects in urinary albumin excretion and renal function changes by delapril and manidipine in normotensive type 2 diabetic patients with microalbuminuria
38. Effect of manidipine hydrochloride on persistent microalbuminuria in normotensive diabetic patients
39. Effects of manidipine hydrochloride on proteinuria in diabetic patients with hypertension
40. The effect of angiotensin converting enzyme inhibitor and calcium antagonists on urinary albumin excretion in non-insulin-dependent diabetic patients
41. Effects of benazepril and manidipine on the progression of diabetic nephropathy
42. Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy
43. Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in patients with mild to moderate essential hypertension: A randomized trial with one-year follow-up
44. Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension
45. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives
46. Manidipine has less oedematigenous potential than amlodipine
47. Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats
48. Manidipine hydrochloride [CV-4093(2HCl)]
49. Effects of manidipine and other calcium antagonists on rat renal arcuate arteries
50. Antihypertensive action, calcium channel blocking action and receptor binding activity of manidipine hydrochloride in experimental animals
51. Practitioner' s Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (the PATE-Hypertension study) in Japan
52. Antihypertensive efficacy of amlodipine and manidipine on 24-hour blood pressure in patients with essential hypertension
53. Long-term efficacy and safety of manidipine hydrochloride in the treatment of hypertension patients
54. Clinical study of manidipine hydrochloride in essential hypertension: A double-blind controlled study with nicardipine hydrochloride
55. A 3-year long-term evaluation of the efficacy and safety of manidipine hydrochloride (Calslot tablet) in the elderly with essential hypertension: A multicentre collaborative study
56. Efficacy, tolerability and impact on quality of life and long-term treatment with manidipine or amlodipine in patients with essential hypertension
57. Evaluation of the antihypertensive and metabolic efficacy of manidipine (10/20 mg/day) in the treatment of mild to moderate essential arterial hypertension in patients with noninsulin dependent diabetes mellitus. A randomised, parallel group study versus amlodipine (5/10 mg/day)
58. Evaluation of the antihypertensive and metabolic effect of manidipine (10/20 mg/day) in the treatment of essential arterial hypertension with non insulin dependent diabetes mellitus (type II). Multicentre, randomized, double blind, controlled parallel group, comparative trial with Enalapril (10/20 mg/day)
59. Antihypertensive treatment in the nephrotic patients
60. Effects of manidipine hydrochloride, nisoldipine and nitrendipine on renal hemodynamics and function in stroke-prone spontaneously hypertensive rats (SHRSP)
61. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats
62. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats
63. The antiatherosclerotic effect of the calcium antagonists and their implications in hypertension
64. Effects of different dihydropyridine calcium antagonists on pretibial subcutaneous tissue pressure in hypertensive patients
65. Effect of manidipine chloride on various aspects of endocrine function, including plasma levels of endothelin-1 and human atrial natriuretic peptide, in patients with essential hypertension
66. Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus
67. Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects
68. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls
69. Pharmacokinetic study of CV-4093 (2 HCl) at single dose on healthy subjects
70. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions
71. Effect of dihydropyridine calcium channel blockers on the plasma digoxin level
72. Effect of manidipine, a novel calcium channel blocker, on quality of life in hypertensive patients
73. Blood pressure screening, management and control in England: Results from the health survey for England 1994
74. World Health Organization - International Society of Hypertension Guideline for the Management of Hypertension
75. Hypertension and stroke in Asia: Prevalence, control and strategies in developing countries for prevention
76. Hypertension in East Asia
77. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society
78. Predictors of cardiovascular morbidity in treated hypertension: Results from the Primary Preventive Trial in Goteborg
79. Mortality in patients of the Glasgow Blood Pressure Clinic
80. Calcium antagonists: Not appropriate as first line antihypertensive agents
81. Do calcium channel blockers increase the risk of cancer?
82. Calcium channel blockade and incidence of cancer in aged populations
83. Role of a third generation calcium antagonist in the management of hypertension
84. Calcium antagonists should continue to be used for first-line treatment of hypertension
85. Calcium antagonists: Still appropriate as first-line antihypertensive agents
86. Calcium channel blockers: The jury is still out on whether they cause heart attacks and suicide
87. Calcium-channel blockers for hypertension - Uncertainty continues
88. Renal protection and antihypertensive drugs: Current status
89. The renoprotective effect of antihypertensive drugs